Your browser doesn't support javascript.
loading
Clinical advances on danoprevir and triple therapy of danoprevir with Peg IFN and ribavirin regimen in treatment of chronic hepatitis C / 中华临床感染病杂志
Chinese Journal of Clinical Infectious Diseases ; (6): 84-89, 2018.
Article in Chinese | WPRIM | ID: wpr-709033
ABSTRACT
So far, thirty-seven clinical trials of danoprevir in treatment of chronic hepatitis C (CHC)have been completed globally,in which more than 2 600 patients were involved.The clinical trials among Chinese patients with genotype 1 CHC showed that the sustained virologic response(SVR)rate reached to 97.0% after twelve-week treatment of danoprevir combined with PR regimen(Peg IFN and ribavirin), and the safety was good.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Clinical Infectious Diseases Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Clinical Infectious Diseases Year: 2018 Type: Article